{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:31:35Z","timestamp":1780054295032,"version":"3.54.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.clinbiochem.2021.04.003","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T20:03:40Z","timestamp":1618949020000},"page":"99-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The analytical performance of six urine drug screens on cobas 6000 and ARCHITECT i2000 compared to LC-MS\/MS gold standard"],"prefix":"10.1016","volume":"93","author":[{"given":"Mohamed","family":"Abou El Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Colantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9895-1052","authenticated-orcid":false,"given":"Sergei","family":"Likhodii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam A.","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2021.04.003_b0005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.36076\/ppj.2013\/16\/593","article-title":"Can we predict addiction to opioid analgesics? A possible tool to estimate the risk of opioid addiction in patients with pain","volume":"16","author":"Skala","year":"2013","journal-title":"Pain Phys."},{"issue":"12","key":"10.1016\/j.clinbiochem.2021.04.003_b0010","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/pme.12221","article-title":"Addition of objective data to identify risk for medication misuse and abuse: the inconsistency score","volume":"14","author":"Hamill-Ruth","year":"2013","journal-title":"Pain Med."},{"issue":"8","key":"10.1016\/j.clinbiochem.2021.04.003_b0015","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/jat\/32.8.530","article-title":"Urine drug testing of chronic pain patients: licit and illicit drug patterns","volume":"32","author":"Cone","year":"2008","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0020","first-page":"359","article-title":"KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain","volume":"17","author":"Darragh","year":"2014","journal-title":"Pain Phys."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0025","doi-asserted-by":"crossref","unstructured":"M. B\u00f6ttcher, O. Beck, Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment, J. Anal. Toxicol. 29 (2005) 769\u2013776.","DOI":"10.1093\/jat\/29.8.769"},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0030","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.cca.2012.03.017","article-title":"Therapeutic monitoring of benzodiazepines in the management of pain: current limitations of point of care immunoassays suggest testing by mass spectrometry to assure accuracy and improve patient safety","volume":"413","author":"Mikel","year":"2012","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"10.1016\/j.clinbiochem.2021.04.003_b0035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00414-005-0544-x","article-title":"Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?","volume":"119","author":"Pavlic","year":"2005","journal-title":"Int. J. Legal Med."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0040","first-page":"273","article-title":"An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients","volume":"13","author":"Pesce","year":"2010","journal-title":"Pain Phys."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1258\/acb.2009.009172","article-title":"Measurement of benzodiazepines in urine by liquid chromatography-tandem mass spectrometry: confirmation of samples screened by immunoassay","volume":"47","author":"Glover","year":"2010","journal-title":"Ann. Clin. Biochem."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.04.003_b0050","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cll.2012.06.004","article-title":"The utility of immunoassays for urine drug testing","volume":"32","author":"Melanson","year":"2012","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.forsciint.2005.03.022","article-title":"Drug screening and confirmation by GC-MS: comparison of EMIT II and Online KIMS against 10 drugs between US and England laboratories","volume":"157","author":"Lu","year":"2006","journal-title":"Forensic Sci. Int."},{"issue":"7","key":"10.1016\/j.clinbiochem.2021.04.003_b0060","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1526-4637.2012.01350.x","article-title":"Interpretation of urine drug testing in pain patients","volume":"13","author":"Pesce","year":"2012","journal-title":"Pain Med."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0065","first-page":"S5","article-title":"Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians\u2019 (ASIPP) Guidelines","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0070","series-title":"Toxicity and Drug Testing","article-title":"Diagnostic accuracy and interpretation of urine drug testing for pain patients: an evidence-based approach","author":"Pesce","year":"2012"},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0075","unstructured":"E.L.J. Langman, P.J. Jannetto, Monitor drug therapy in pain management patients, Lab. Med. (n.d.) 109."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0080","doi-asserted-by":"crossref","unstructured":"J.M. Reschly-Krasowski, M.D. Krasowski, A difficult challenge for the clinical laboratory: accessing and interpreting manufacturer cross-reactivity data for immunoassays used in urine drug testing, Acad Pathol. 5 (2018).","DOI":"10.1177\/2374289518811797"},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0085","first-page":"E583","article-title":"Clinical benefits of direct-to-definitive testing for monitoring compliance in pain management","volume":"21","author":"Gencheva","year":"2018","journal-title":"Pain Physician."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinms.2018.06.001","article-title":"Understanding the strategic landscape surrounding the implementation of mass spectrometry in the clinical laboratory: A SWOT analysis","volume":"9","author":"Vogeser","year":"2018","journal-title":"Clin. Mass Spectrom."},{"issue":"4","key":"10.1016\/j.clinbiochem.2021.04.003_b0095","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1373\/jalm.2017.025304","article-title":"Using clinical laboratory tests to monitor drug therapy in pain management patients","volume":"2","author":"Jannetto","year":"2018","journal-title":"J. Appl. Lab Med."},{"issue":"7","key":"10.1016\/j.clinbiochem.2021.04.003_b0100","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jat\/bku075","article-title":"False-positive interferences of common urine drug screen immunoassays: a review","volume":"38","author":"Saitman","year":"2014","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1373\/49.3.357","volume":"49","author":"Wu","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0110","first-page":"33","article-title":"Urine drug tests: ordering and interpreting results","volume":"99","author":"Kale","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0115","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain-United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.clinbiochem.2021.04.003_b0120","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cll.2016.07.006","article-title":"Common interferences in drug testing","volume":"36","author":"Smith","year":"2016","journal-title":"Clin. Lab Med."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0125","unstructured":"K.L. Lynch, Chapter 6 - Toxicology: liquid chromatography mass spectrometry, (n.d.) 22."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0130","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1360-0443.2010.03052.x","article-title":"Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system","volume":"105","author":"Boscarino","year":"2010","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.clinbiochem.2021.04.003_b0135","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jpain.2007.02.432","article-title":"Substance use disorders in a primary care sample receiving daily opioid therapy","volume":"8","author":"Fleming","year":"2007","journal-title":"J. Pain"},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0140","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/FTD.0b013e3181c11fba","article-title":"LC-MS\/MS extends the range of drug analysis in pain patients","volume":"31","author":"Mikel","year":"2009","journal-title":"Ther. Drug Monit."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.04.003_b0145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jat\/bks003","article-title":"A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse","volume":"36","author":"Melanson","year":"2012","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.clinbiochem.2021.04.003_b0150","doi-asserted-by":"crossref","first-page":"259","DOI":"10.36076\/ppj.2011\/14\/259","article-title":"Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC\/MS\/MS) of urine drug testing","volume":"14","author":"Manchikanti","year":"2011","journal-title":"Pain Physician"},{"issue":"1","key":"10.1016\/j.clinbiochem.2021.04.003_b0155","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4065\/83.1.66","article-title":"Urine drug screening: practical guide for clinicians","volume":"83","author":"Moeller","year":"2008","journal-title":"Mayo Clin. Proc."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912021001065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912021001065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:09:59Z","timestamp":1762114199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912021001065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":31,"alternative-id":["S0009912021001065"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.04.003","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The analytical performance of six urine drug screens on cobas 6000 and ARCHITECT i2000 compared to LC-MS\/MS gold standard","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}